DDInter1255 DDInter1376
Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects. Nadolol was granted FDA approval on 10 December 1979.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Nadolol {u} (Compound) resembles {v} (Compound) Carteolol
Nadolol {u} (Compound) treats {v} (Disease) hypertension
Nadolol {u} (Compound) binds {v} (Gene) ABCB1
Nadolol {u} (Compound) upregulates {v} (Gene) EVL
Nadolol {u} (Compound) downregulates {v} (Gene) CSRP1
Nadolol {u} (Compound) causes {v} (Side Effect) Body temperature increased
Nadolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magaldrate
Nadolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Liothyronine
Nadolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Scopolamine
Nadolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Nadolol (Compound) resembles Carteolol (Compound)
Nadolol (Compound) treats hypertension (Disease)
Nadolol (Compound) binds ABCB1 (Gene)
Nadolol (Compound) upregulates EVL (Gene)
Nadolol (Compound) downregulates CSRP1 (Gene)
Nadolol (Compound) causes Body temperature increased (Side Effect)
Nadolol may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Nadolol may cause a minor interaction that can limit clinical effects when taken with Liothyronine
Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine
Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide